Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
19.06. | Alzinova AB: Alzinova's ALZ-101 vaccine shows new promising results in normalizing protective antibody levels in Alzheimer's disease patients | 111 | GlobeNewswire (Europe) | Alzinova AB (ALZ) announces new clinical results showing that healthy elderly people naturally have high levels of protective antibodies against toxic amyloid-ß oligomers, which are reduced in Alzheimer's... ► Artikel lesen | |
17.06. | Alzinova AB: Alzinova selects Worldwide Clinical Trials as CRO partner for Phase 2 study of ALZ-101 | 340 | GlobeNewswire (Europe) | Alzinova AB (Nasdaq First North: ALZ) today announces a strategic collaboration with Worldwide Clinical Trials ("Worldwide"), a global leader in neuroscience studies, appointing them as the Clinical... ► Artikel lesen | |
ALZINOVA Aktie jetzt für 0€ handeln | |||||
28.05. | Alzinova AB: Bulletin from the Annual General Meeting of Alzinova AB (publ) | 102 | GlobeNewswire (Europe) | Alzinova AB (publ) (the "Company") held its Annual General Meeting ("AGM") in Gothenburg on 28 May 2025. The following resolutions were passed at the meeting.
Adoption of the annual accounts and discharge... ► Artikel lesen | |
15.05. | Alzinova AB: Alzinova publishes interim report January - March 2025 | 99 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - March 2025. The full report, which is attached in the press release,... ► Artikel lesen | |
24.04. | Alzinova AB: Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial | 188 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical trial of the vaccine candidate ALZ-101 in early Alzheimer's disease. This... ► Artikel lesen | |
11.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 11.04.2025 | 323 | Xetra Newsboard | Das Instrument J1X BMG4660A1036 HIMALAYA SHIPPING LTD DL1 EQUITY wird cum Kapitalmassnahme gehandelt am 11.04.2025 und ex Kapitalmassnahme am 14.04.2025 The instrument J1X BMG4660A1036 HIMALAYA SHIPPING... ► Artikel lesen | |
02.04. | Alzinova AB: The Board of Directors of Alzinova resolves on a rights issue of shares of approximately SEK 35.7 million | 123 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, CANADA, THE UNITED... ► Artikel lesen | |
27.03. | Alzinova AB: Final results confirm positive phase 1b results with ALZ-101 against Alzheimer's disease | 347 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) today announces that the final analysis of data from the Phase 1b clinical study with the vaccine candidate ALZ-101, which included patients with early Alzheimer's disease... ► Artikel lesen | |
07.03. | Alzinova AB: Bulletin from the Extraordinary General Meeting of Alzinova AB (publ) | 160 | GlobeNewswire (Europe) | The following resolution were passed at the extraordinary general meeting (the "EGM") of Alzinova AB (publ) ("the Company") on 7 March 2025 in Gothenburg.
Long-term incentive program (LTIP 2025:1 for... ► Artikel lesen | |
27.02. | Alzinova AB: Alzinova publishes year-end report 2024 | 209 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the year-end report for the period January - December, and the fourth quarter, 2024. The full report, which is attached... ► Artikel lesen | |
03.02. | Alzinova AB: All study participants have completed the final visit in the Phase 1 study | 225 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) announces that another milestone in the development of the company's vaccine candidate ALZ-101 for Alzheimer's disease has been reached. All study participants have... ► Artikel lesen | |
28.01. | Alzinova AB: Alzinova strategically realigns CMO position to enhance collaboration and drive next development phase | 335 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) hereby announces that the Company's CMO is stepping down from her role after mutual agreement. The basis is a strategic decision to appoint a CMO in place at the Company's... ► Artikel lesen | |
09.12.24 | Alzinova AB: Alzinova reports positive results from the phase 1b extension part of the ALZ-101 study in Alzheimer's disease | 279 | GlobeNewswire (Europe) | ALZ-101 continues to demonstrate a favorable safety and tolerability profile after at least 84 weeks of study inclusion.The immune response from vaccination with ALZ-101 is robust and long-lasting in... ► Artikel lesen | |
14.11.24 | Alzinova AB: Alzinova publishes interim report January - September 2024 | 228 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - September, and the third quarter, 2024. The full interim report, which... ► Artikel lesen | |
22.08.24 | Alzinova AB: Alzinova publishes interim report January - June 2024 | 190 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period April - June, and the first half year, 2024. The full interim report, which is... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |